We can’t show the full text here under this license. Use the link below to read it at the source.
Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice
Greater liver fat and scarring reduction in mice with combined treatment of a diabetes hormone mimic and obeticholic acid
AI simplified
Abstract
Combination therapy with GLP-1R agonist IP118 and FXR agonist obeticholic acid (OCA) significantly reduced liver weight by 29% in mice with nonalcoholic steatohepatitis (NASH).
- OCA alone reduced liver weight and lipid in NASH mice by 17%, but did not affect plasma ALT or AST levels.
- IP118 alone significantly decreased liver weight by 21%, liver lipid by 15%, ALT by 29%, and AST by 27%.
- The combination of OCA and IP118 resulted in greater reductions in liver weight, liver lipid, ALT, and AST compared to either drug alone.
- Therapeutic effects of OCA + IP118 were linked to reductions in body weight of 4.3% and improved glycemic control.
- In diet-induced obese mice, OCA + IP118 decreased body weight by 25.3%, outperforming the 12.5% reduction seen with IP118 alone.
AI simplified